PlasmidFactory

PlasmidFactory

Bielefeld, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PlasmidFactory is a well-established, privately-held German CDMO with over 25 years of experience in nucleic acid manufacturing. It has carved a niche as a specialist in plasmid and, notably, its proprietary minicircle DNA technology, serving the burgeoning cell and gene therapy markets. The company operates a service-based business model, generating revenue by producing high-purity DNA starting materials for clients worldwide, from research to commercial GMP supply. Its value proposition centers on technical expertise in difficult-to-produce constructs, antibiotic-free fermentation, and guaranteed batch yields.

Gene TherapyCRISPRSynthetic Biology

Technology Platform

Proprietary plasmid and minicircle DNA manufacturing platform, featuring antibiotic-free fermentation, scalable GMP production up to 10g/run, and bespoke technology for difficult constructs (e.g., ITRAAV, PolyA120) and minicircle DNA for AAV and CAR-T applications.

Opportunities

Rapid growth in cell and gene therapy and mRNA therapeutics is driving increased demand for high-quality plasmid and minicircle DNA as critical starting materials.
The company's expansion into GMP manufacturing and its proprietary minicircle technology position it to capture high-value contracts for late-stage clinical and commercial supply.

Risk Factors

Revenue is dependent on the funding and success of client biotech companies, which can be volatile.
As a GMP manufacturer, it faces significant regulatory compliance risks, and the competitive landscape for CDMO services in nucleic acids is intensifying.

Competitive Landscape

PlasmidFactory competes with other specialized plasmid DNA CDMOs (e.g., VGXI, Aldevron, LakePharma) and the in-house manufacturing capabilities of large biopharma. Its differentiation lies in its deep focus on plasmids/minicircles, proprietary technology for difficult sequences, antibiotic-free production, and a 25-year track record in this specific niche.